Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Barbara MacGregor"'
Autor:
Andreas Teske, Gunter Wegener, Jeffrey P. Chanton, Dylan White, Barbara MacGregor, Daniel Hoer, Dirk de Beer, Guangchao Zhuang, Matthew A. Saxton, Samantha B. Joye, Daniel Lizarralde, S. Adam Soule, S. Emil Ruff
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Cold seeps and hydrothermal vents are seafloor habitats fueled by subsurface energy sources. Both habitat types coexist in Guaymas Basin in the Gulf of California, providing an opportunity to compare microbial communities with distinct physiologies a
Externí odkaz:
https://doaj.org/article/26d921f03f624b44b73f54e85e6990b9
Publikováno v:
Frontiers in Microbiology, Vol 10 (2019)
Orange filamentous Beggiatoaceae form massive microbial mats on hydrothermal sediments in Guaymas Basin; these bacteria are considered to oxidize sulfide with nitrate and nitrite as electron acceptors. From a previously analyzed genome of an orange B
Externí odkaz:
https://doaj.org/article/9c92c2bf26aa40b0ac849cdfa28f77e2
Publikováno v:
Frontiers in Microbiology, Vol 7 (2016)
A major fraction of the petroleum hydrocarbons discharged during the 2010 Macondo oil spill became associated with and sank to the seafloor as marine snow flocs. This sedimentation pulse induced the development of distinct bacterial communities. Betw
Externí odkaz:
https://doaj.org/article/392a48877c3948a39b7384a6257437cd
Autor:
Beverly E. Flood, Dalton J. Leprich, Ryan C. Hunter, Nathalie Delherbe, Barbara MacGregor, Michael Van Nieuwenhze, Jake V. Bailey
Until recently, the cellular envelopes of bacteria were regarded as static and rigid relative to those of eukaryotes. While investigating peptidoglycan synthesis in populations of giant sulfur bacteria, Candidatus Thiomargarita spp., we observed inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a839549461cead2546be28b7581cc56
https://doi.org/10.1101/2022.04.11.487978
https://doi.org/10.1101/2022.04.11.487978
Autor:
Barbara MacGregor-Cortelli, David N. Silvers, Alexander G. Marneros, Sameera Husain, Gerard J. Nuovo, Ellen Neylon, Molly Patterson, Jasmine Zain, Owen A. O'Connor, Marc E. Grossman
Publikováno v:
Blood. 113:6338-6341
Pralatrexate is a novel antifolate, which shows increased antitumor activity in human tumor xenograft studies in mice compared with methotrexate. We investigated the effects of pralatrexate in a patient with adult T-cell lymphoma/leukemia with signif
Autor:
Klaus J. Busam, Ellen Neylon, David P. Schenkein, Dixie Lee Esseltine, Mithat Gonen, Anthony Boral, Julie Teruya-Feldstein, Barbara MacGregor-Cortelli, John F. Gerecitano, John J. Wright, Andre Goy, Dana L. Sachs, Owen A. O'Connor
Publikováno v:
British Journal of Haematology. 134:391-398
Summary Bortezomib is the first proteasome inhibitor to be approved for use in haematological malignancies. Although a rash has been described as a common adverse event associated with the drug, it has not been well characterised. Based on three phas
Autor:
Carol S. Portlock, Molly Patterson, Jill Mastrella, Steven M. Horwitz, Diane R. Mould, Barbara MacGregor-Cortelli, Frank Sirotnak, Rachel Hamelers, Owen A. O'Connor, Michael Saunders, Debra M. Sarasohn, Martin Fleisher, Andrew D. Zelenetz, Craig H. Moskowitz, Ellen Neylon, Venkatraman E. Seshan, Paul A. Hamlin
Purpose To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma. Patients and Methods Pralatrexate, initially given at a dose of 135 mg/m2 on an every-other-week basis, was associated with stomatitis. A re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43f77b284aa3ffff11fe0e7e1195aa7
https://europepmc.org/articles/PMC3651599/
https://europepmc.org/articles/PMC3651599/
Autor:
Debra M. Sarasohn, Andrew D. Zelenetz, Martin Fleischer, Otila Dumetrescu, Barbara MacGregor-Cortelli, Craig H. Moskowitz, Diane R. Mould, Steven M. Horwitz, Ariela Noy, Paul A. Hamlin, Frank Sirotnak, Owen A. O'Connor, David J. Straus, Ellen Neylon, Carol S. Portlock
Publikováno v:
British journal of haematology. 139(3)
T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma
Autor:
Jamie Muzzy, Dixie Lee Esseltine, Susan F. Slovin, John J. Wright, Barbara MacGregor-Cortelli, Michael D. Stubblefield, Howard I. Scher, David P. Schenkein, Owen A. O'Connor
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 18(5)
Aims Bortezomib (Velcade ® ), a novel proteasome inhibitor, has shown promise in the treatment of malignancies, including multiple myeloma and non-Hodgkin's lymphoma. Several studies have identified neuropathy as a potentially dose-limiting side eff
Autor:
Owen A. O'Connor, Elizabeth Trehu, David J. Straus, Michael D. Stubblefield, John J. Wright, Jamie Muzzy, Paul A. Hamlin, Otila Dumetrescu, Dixie Lee Esseltine, Julian Adams, Carol S. Portlock, Craig H. Moskowitz, Andrew D. Zelenetz, Barbara MacGregor-Cortelli, David P. Schenkein, Elizabeth Choi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(4)
Purpose To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL). Patients and Methods Patients with indolent and MCL were eligible. Bortezomib was given at a dose of 1.